Drug Development
Company to develop topical eyedrop treatment for wet macular degeneration
Published in Obesity and Diabetes Week, August 29th, 2005
TargeGen, Inc., a biopharmaceutical company developing small molecule drugs for the treatment of edema and angiogenesis related diseases, announced that TG 100801, a selective topically administered multi-target kinase inhibitor, has been designated a lead drug for clinical developmentin the treatment of major eye diseases including macular degeneration, diabetic macular edema and diabetic retinopathy.
Current treatments for wet macular degeneration have demonstrated limited efficacy to date and require injection into the eye, thus increasing the risk of infection and retinal detachment.
Pre-clinical studies conducted to date with TG100801 have shown...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Insulin Resistance
Adiponectin prevents release of insulin resistance-inducing factors - Insulin Resistance
Alternative definitions of impaired fasting glucose developed - Insulin Resistance
Exercise-induced increase in muscle insulin sensitivity examined - Obesity and Diabetes
CART knock-out mice have glucose intolerance and increased body weight - Obesity and Diabetes
Insulin resistance reduces expression of heat shock protein 72 - Angiotensin Converting Enzyme
Study investigated ACE I/D polymorphism in pediatric cancer patients - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
